PIPELINES
Pipeline Progress
Driving 8 Proprietary Pipelines
Across 3 Core Therapeutic Areas
Pre-clinical efficacy validation completed or underway for Parkinson's (2) and Alzheimer's (1).
Exploratory pipelines targeting Alzheimer's, metabolic disorders, and aging for long-term scalability.
Parkinson’s candidates PD-29 and PD-33: Completed efficacy studies in mouse models.
Alzheimer’s candidate AD-08: Undergoing efficacy testing in mice
Exploratory pipelines targeting Alzheimer's, metabolic disorders, and aging for long-term scalability.
Parkinson’s candidates PD-29 and PD-33: Completed efficacy studies in mouse models.
Alzheimer’s candidate AD-08: Undergoing efficacy testing in mice
Cosmetics
Ceramide-Zein Complex Nanoparticles
Ceramide-Zein Complex Nanoparticles: Manufacturing Method and Applications (Patent Application No.: 10-2023-0177328)
Our proprietary technology delivers Ceramide-Zein complex nanoparticles by encapsulating Ceramide within heat-denatured Zein protein. This targeted 3D structural modification significantly enhances the stability and water solubility of Ceramide, making it an ideal high-performance ingredient for aqueous or water-dispersible cosmetic formulations.
Our proprietary technology delivers Ceramide-Zein complex nanoparticles by encapsulating Ceramide within heat-denatured Zein protein. This targeted 3D structural modification significantly enhances the stability and water solubility of Ceramide, making it an ideal high-performance ingredient for aqueous or water-dispersible cosmetic formulations.
Cosmetics
Sedum takesimense Extract Nanocomposites
Sedum takesimense Extract-Carbohydrate Nanocomposite and Manufacturing Method Thereof (Patent No.: 10-2217554-0000)
Sedum takesimense Extract-Protein Nanocomposite and Manufacturing Method Thereof(Patent No.: 10-2127634-0000)
* Biotechnology Journal, 15, 2000080 (2020)
Sedum takesimense Extract-Protein Nanocomposite and Manufacturing Method Thereof(Patent No.: 10-2127634-0000)
* Biotechnology Journal, 15, 2000080 (2020)
Functional Foods
GBLac™ Smart Life Probiotics
.jpg)
Functional Foods
Probiotic-Driven L-DOPA Production
Composition for preventing, improving or treating Parkinson's disease comprising combination of lactic acid bacteria and L-tyrosine. (Patent No.: 10-2903891-0000)
Our proprietary strains—including Lactiplantibacillus plantarum, L. paraplantarum, and L. pentosus—demonstrate exceptional enzymatic activity in converting L-Tyrosine into Levodopa (L-DOPA).
By leveraging these specific probiotic strains in combination with L-Tyrosine, we have engineered a formulation designed to facilitate endogenous Levodopa production in vivo.
This specialized composition serves as a foundational platform for:
Medical Grade Supplements (Nutraceuticals) for neurological health improvement.
Therapeutic Pharmaceuticals targeted at the prevention and treatment of Parkinson’s Disease.
Our proprietary strains—including Lactiplantibacillus plantarum, L. paraplantarum, and L. pentosus—demonstrate exceptional enzymatic activity in converting L-Tyrosine into Levodopa (L-DOPA).
By leveraging these specific probiotic strains in combination with L-Tyrosine, we have engineered a formulation designed to facilitate endogenous Levodopa production in vivo.
This specialized composition serves as a foundational platform for:
Medical Grade Supplements (Nutraceuticals) for neurological health improvement.
Therapeutic Pharmaceuticals targeted at the prevention and treatment of Parkinson’s Disease.
Therapeutics
Glabridin-Zein Complex Nanoparticles
* Glabridin-Zein Complex Nanoparticles: Manufacturing Method and Applications (Patent No.: 10-1902846-0000)
* Food Hydrocolloids, 91, 290-300 (2019)
Our proprietary Glabridin-Zein complex nanoparticles encapsulate Glabridin within Zein protein to maximize its bioactivity in aqueous environments. This specialized formulation significantly enhances stability, providing a high-performance solution for antioxidant and antibacterial applications across the food and pharmaceutical sectors.
* Food Hydrocolloids, 91, 290-300 (2019)
Our proprietary Glabridin-Zein complex nanoparticles encapsulate Glabridin within Zein protein to maximize its bioactivity in aqueous environments. This specialized formulation significantly enhances stability, providing a high-performance solution for antioxidant and antibacterial applications across the food and pharmaceutical sectors.
Therapeutics
Bio-Conversion Technology for Levodopa (L-DOPA)
* Method for Producing Levodopa (L-DOPA) from L-Tyrosine (Patent No.: 10-2798366-0000)
Our proprietary probiotic-based formulation leverages the synergistic combination of specific strains and L-Tyrosine to facilitate endogenous Levodopa production in vivo. This precision-engineered composition is designed for high-performance applications in both nutraceuticals and pharmaceuticals, specifically targeting the prevention, management, and treatment of Parkinson’s Disease
Our proprietary probiotic-based formulation leverages the synergistic combination of specific strains and L-Tyrosine to facilitate endogenous Levodopa production in vivo. This precision-engineered composition is designed for high-performance applications in both nutraceuticals and pharmaceuticals, specifically targeting the prevention, management, and treatment of Parkinson’s Disease
Get a 1:1 consultation with elegslab today.
Contact us, and we’ll get back to you within 3 business days.